AUTL announced the presentation of top-line data from the Pivotal Phase 2 FELIX study of obe-cel in adult r/r B-cell Acute Lymphoblastic Leukemia (B-ALL) at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting. The study showed that 76% of patients treated achieved a response (CR/CRi), and the primary endpoint has been met based on previously communicated interim analysis$Autolus Therapeutics(AUTL)$